- Home
- LNZA vs XLO Comparison
LNZA vs XLO Comparison
Compare LNZA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- XLO
- Stock Information
- Founded
- LNZA 2005
- XLO 2016
- Country
- LNZA United States
- XLO United States
- Employees
- LNZA N/A
- XLO N/A
- Industry
- LNZA Major Chemicals
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- XLO Health Care
- Exchange
- LNZA Nasdaq
- XLO Nasdaq
- Market Cap
- LNZA 43.7M
- XLO 42.2M
- IPO Year
- LNZA N/A
- XLO 2021
- Fundamental
- Price
- LNZA $0.20
- XLO $0.88
- Analyst Decision
- LNZA Hold
- XLO Buy
- Analyst Count
- LNZA 2
- XLO 1
- Target Price
- LNZA $2.00
- XLO $4.00
- AVG Volume (30 Days)
- LNZA 988.3K
- XLO 2.7M
- Earning Date
- LNZA 05-19-2025
- XLO 05-08-2025
- Dividend Yield
- LNZA N/A
- XLO N/A
- EPS Growth
- LNZA N/A
- XLO N/A
- EPS
- LNZA N/A
- XLO N/A
- Revenue
- LNZA $48,831,000.00
- XLO $9,274,000.00
- Revenue This Year
- LNZA $86.52
- XLO $299.61
- Revenue Next Year
- LNZA N/A
- XLO $1.99
- P/E Ratio
- LNZA N/A
- XLO N/A
- Revenue Growth
- LNZA N/A
- XLO N/A
- 52 Week Low
- LNZA $0.14
- XLO $0.62
- 52 Week High
- LNZA $3.26
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- LNZA 39.55
- XLO 54.43
- Support Level
- LNZA $0.22
- XLO $0.81
- Resistance Level
- LNZA $0.27
- XLO $0.92
- Average True Range (ATR)
- LNZA 0.03
- XLO 0.10
- MACD
- LNZA 0.00
- XLO 0.01
- Stochastic Oscillator
- LNZA 5.26
- XLO 43.04
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).